doi: 10.1021/jm8004527.
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase
Dirk A Heerding 1, Nelson Rhodes, Jack D Leber, Tammy J Clark, Richard M Keenan, Louis V Lafrance, Mei Li, Igor G Safonov, Dennis T Takata, Joseph W Venslavsky, Dennis S Yamashita, Anthony E Choudhry, Robert A Copeland, Zhihong Lai, Michael D Schaber, Peter J Tummino, Susan L Strum, Edgar R Wood, Derek R Duckett, Derek Eberwein, Victoria B Knick, Timothy J Lansing, Randy T McConnell, Shuyun Zhang, Elisabeth A Minthorn, Nestor O Concha, Gregory L Warren, Rakesh Kumar
Affiliations
- PMID:18800763
- DOI: 10.1021/jm8004527
Item in Clipboard
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase
Dirk A Heerding et al. J Med Chem..
Display options
Format
Display options
Format
Abstract
Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC 50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3beta. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3beta phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.
Similar articles
- Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, Kahana JA, Geske RS, Kleymenova EV, Choudhry AE, Lai Z, Leber JD, Minthorn EA, Strum SL, Wood ER, Huang PS, Copeland RA, Kumar R.Rhodes N, et al.Cancer Res. 2008 Apr 1;68(7):2366-74. doi: 10.1158/0008-5472.CAN-07-5783.Cancer Res. 2008.PMID:18381444
- Aminofurazans as potent inhibitors of AKT kinase.Rouse MB, Seefeld MA, Leber JD, McNulty KC, Sun L, Miller WH, Zhang S, Minthorn EA, Concha NO, Choudhry AE, Schaber MD, Heerding DA.Rouse MB, et al.Bioorg Med Chem Lett. 2009 Mar 1;19(5):1508-11. doi: 10.1016/j.bmcl.2009.01.002. Epub 2009 Jan 9.Bioorg Med Chem Lett. 2009.PMID:19179070
- Mechanism and management of AKT inhibitor-induced hyperglycemia.Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, Brown KK, Kumar R.Crouthamel MC, et al.Clin Cancer Res. 2009 Jan 1;15(1):217-25. doi: 10.1158/1078-0432.CCR-08-1253.Clin Cancer Res. 2009.PMID:19118049
- Structure-based optimization of PKCtheta inhibitors.Mosyak L, Xu Z, Joseph-McCarthy D, Brooijmans N, Somers W, Chaudhary D.Mosyak L, et al.Biochem Soc Trans. 2007 Nov;35(Pt 5):1027-31. doi: 10.1042/BST0351027.Biochem Soc Trans. 2007.PMID:17956269Review.
- Akt signalling in health and disease.Hers I, Vincent EE, Tavaré JM.Hers I, et al.Cell Signal. 2011 Oct;23(10):1515-27. doi: 10.1016/j.cellsig.2011.05.004. Epub 2011 May 17.Cell Signal. 2011.PMID:21620960Review.
Cited by
- Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.Yu X, Xu J, Shen Y, Cahuzac KM, Park KS, Dale B, Liu J, Parsons RE, Jin J.Yu X, et al.J Med Chem. 2022 Feb 24;65(4):3644-3666. doi: 10.1021/acs.jmedchem.1c02165. Epub 2022 Feb 4.J Med Chem. 2022.PMID:35119851Free PMC article.
- Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE.Singleton KR, et al.Cancer Res. 2015 Oct 15;75(20):4398-406. doi: 10.1158/0008-5472.CAN-15-0509. Epub 2015 Sep 10.Cancer Res. 2015.PMID:26359452Free PMC article.
- The actin-myosin regulatory MRCK kinases: regulation, biological functions and associations with human cancer.Unbekandt M, Olson MF.Unbekandt M, et al.J Mol Med (Berl). 2014 Mar;92(3):217-25. doi: 10.1007/s00109-014-1133-6. Epub 2014 Feb 20.J Mol Med (Berl). 2014.PMID:24553779Free PMC article.Review.
- Upregulation of Nicotinic Acetylcholine Receptor alph4+beta2 through a Ligand-Independent PI3Kbeta Mechanism That Is Enhanced by TNFalpha and the Jak2/p38Mapk Pathways.Rogers SW, Gahring LC.Rogers SW, et al.PLoS One. 2015 Nov 30;10(11):e0143319. doi: 10.1371/journal.pone.0143319. eCollection 2015.PLoS One. 2015.PMID:26619345Free PMC article.
- PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.Silva JM, Deuker MM, Baguley BC, McMahon M.Silva JM, et al.Pigment Cell Melanoma Res. 2017 May;30(3):353-367. doi: 10.1111/pcmr.12586. Epub 2017 Apr 20.Pigment Cell Melanoma Res. 2017.PMID:28233937Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Miscellaneous